Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells

• Published in: Biochemical pharmacology Vol. 69; no. 1; pp. 41 - 48
• Main Authors: Juan, Shu-Hui, Cheng, Tzu-Hurng, Lin, Hui-Chen, Chu, Yen-Ling, Lee, Wen-Sen
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2005; Elsevier Science
• Subjects: Aorta - cytology; Aorta - drug effects; Aorta - enzymology; Biological and medical sciences; c-Jun N-terminal kinase; Cell Line; Dose-Response Relationship, Drug; Extracellular signal-regulated kinase 1/2; Gene Expression Regulation, Enzymologic - drug effects; Gene Expression Regulation, Enzymologic - physiology; General and cellular metabolism. Vitamins; Heme Oxygenase (Decyclizing) - biosynthesis; Heme Oxygenase (Decyclizing) - genetics; Heme Oxygenase-1; Human aortic smooth muscle cell; Humans; I kappa-B alpha; Medical sciences; Membrane Proteins; Mitogen-activated protein kinases; Muscle, Smooth, Vascular - cytology; Muscle, Smooth, Vascular - drug effects; Muscle, Smooth, Vascular - enzymology; Nuclear factor-κB; Pharmacology. Drug treatments; Resveratrol; Stilbenes - pharmacology; NBT; c-Jun N-terminal kinase; HASMC; JNK; Heme oxygenase-1; Extracellular signal-regulated kinase 1/2; HO-1; Nuclear factor-κB; IκBα; NF-κB; ERK1/2; Act D; BCIP; Resveratrol; I kappa-B alpha; Cyclo; Human aortic smooth muscle cell; MAPKs; Mitogen-activated protein kinases; Extracellular signal-regulated protein kinase; Smooth muscle; Red wine; Polyphenol; Blood vessel; Aorta; Transcription factor NFκB; Mechanism of action; Human; Enzyme; Cardioprotective agent; Heme oxygenase (decyclizing); Mitogen-activated protein kinase; Antioxidant; In vitro; Artery; Circulatory system; Oxidoreductases
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2004.09.015

Resveratrol-mediated heme oxygenase-1 (HO-1) induction has been shown to occur in primary neuronal cultures and is thought to have potential neuroprotective action. Further, antioxidant properties of resveratrol have been reported to protect against coronary heart disease. We attempted to examine resveratrol's HO-1 inducing potency and its induction regulation in human aortic smooth muscle cells (HASMC). We showed that resveratrol-mediated HO-1 induction occurred in concentration- and time-dependent manners, but only at low concentrations (1–10
μM), and that it was modulated at both the transcription and translation levels. Additionally, the results of our study showed that nuclear factor-kappa B (NF-κB) inhibitors eliminated resveratrol-mediated HO-1 induction and promoter activity, and that deletion of NF-κB binding sites in the HO-1 promoter region strongly reduced promoter activity, suggesting involvement of the NF-κB pathway in HO-1 induction by resveratrol. Suppression of NF-κB activity by resveratrol at high concentrations (≥20
μM) has been reported to be attributed to its anti-inflammatory and anti-oxidative properties. Likewise, we showed that resveratrol at concentrations of ≥20
μM blocked the activity of NF-κB through suppression of I kappa-B alpha (IκBα) phosphorylation, which caused inhibition of HO-1 induction. Conversely, resveratrol in a range of 1–10
μM enhanced the phosphorylation and degradation of IκBα, a key step in NF-κB activation, resulting in HO-1 induction. Collectively, we suggest that resveratrol-mediated HO-1 expression occurs, at least in part, through the NF-κB pathway, which might contribute to resveratrol's vascular-protective effect at physiological concentrations after moderate red wine consumption.